Yuriy Slutskyy's questions to Intellia Therapeutics Inc (NTLA) leadership • Q2 2025
Question
Representing Kostas Biliouris at BMO Capital Markets, Yuriy Slutskyy asked for the company's latest thoughts on the potential drivers of Grade 4 liver function test (LFT) changes observed after Nexi treatment.
Answer
President and CEO John Leonard corrected that the event was a Grade 1 (mild) elevation by drug-induced liver injury scoring, not Grade 4. He reported the patient was asymptomatic, has returned to baseline, and remains in the study. He stated the company's belief is that the event is unlikely to be directly related to the LNP delivery system and the cause remains under investigation.